Pharmaceuticals - London, England, United Kingdom
Founded in 2009, Lamicare Health initially focused its efforts on developing the active ingredient CEM-K™, a highly efficacious, proprietary extract of sea kelp. Lamicare Health developed Dermikelp®, a range of dermatology products which incorporated the patented CEM-K™ active. Since the successful launch and commercialisation of the Dermikelp®️ brand in South Africa in 2014, the company continues to expand its global sales footprint, including distribution in Europe, UK, SE Asia, Sub-Saharan Africa and the Middle East. We are innovators of novel, proprietary healthcare products and brands, focusing on marine and other natural active ingredients, supported by extensive clinical testing and scientific evidence. Formulation and testing of our first brand, Dermikelp®, a steroid-free, topical treatment range for atopic dermatitis, was developed using our patented active ingredient, CEM-K®, a highly concentrated extract of the giant kelp species Ecklonia maxima, which grows naturally in the clean, cold waters of the Atlantic Coast of southern Africa. Our environmentally friendly process of strip-rotational hand-harvesting and zero waste processing ensures sustainability of source.